ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
-0,77%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,695
-0,11%
Bitcoin
64 838,91
-0,46%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allakos Inc (ALLK)

  7. Allakos Inc (ALLK) Actualités

ALLK

Allakos (ALLK)

Allakos Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALLK
DateHeureSourceTitreSymboleSociété
10/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
07/06/202421h43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLKAllakos Inc
28/05/202413h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLKAllakos Inc
28/05/202413h02GlobeNewswire Inc.Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous UrticariaNASDAQ:ALLKAllakos Inc
09/05/202423h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLKAllakos Inc
09/05/202422h02GlobeNewswire Inc.Allakos Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:ALLKAllakos Inc
14/03/202421h02GlobeNewswire Inc.Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
26/02/202413h02GlobeNewswire Inc.Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024NASDAQ:ALLKAllakos Inc
17/02/202401h08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
14/02/202422h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALLKAllakos Inc
12/02/202413h02GlobeNewswire Inc.Allakos Announces Publication Highlighting AK006 Mast Cell InhibitionNASDAQ:ALLKAllakos Inc
02/02/202418h31Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALLKAllakos Inc
26/01/202422h20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALLKAllakos Inc
16/01/202413h02GlobeNewswire Inc.Allakos Announces a Restructuring to Focus on Development of AK006NASDAQ:ALLKAllakos Inc
16/01/202413h00GlobeNewswire Inc.Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary EndpointsNASDAQ:ALLKAllakos Inc
05/01/202422h02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALLKAllakos Inc
27/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALLKAllakos Inc
13/11/202323h01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLKAllakos Inc
13/11/202322h02GlobeNewswire Inc.Allakos Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
30/08/202322h05GlobeNewswire Inc.Allakos Appoints Neil Graham to its Board of DirectorsNASDAQ:ALLKAllakos Inc
09/08/202322h02GlobeNewswire Inc.Allakos Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
02/08/202322h05GlobeNewswire Inc.Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of DirectorsNASDAQ:ALLKAllakos Inc
12/06/202313h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALLKAllakos Inc
12/06/202313h02GlobeNewswire Inc.Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell InhibitionNASDAQ:ALLKAllakos Inc
05/06/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALLKAllakos Inc
05/06/202313h02GlobeNewswire Inc.Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023NASDAQ:ALLKAllakos Inc
02/06/202322h51Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:ALLKAllakos Inc
09/05/202322h14Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALLKAllakos Inc
09/05/202322h02GlobeNewswire Inc.Allakos Provides Business Update and Reports First Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
20/04/202322h25Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ALLKAllakos Inc
 Showing the most relevant articles for your search:NASDAQ:ALLK

Dernières Valeurs Consultées

LSE
GLUG
Lg Water Etf
LSE
66PS
Sigma Fin.frn08
EU
ISRIJ
BNPP SRIJ iNav
NASDAQ
FGAHOX
Ameriprise Top Picks 202...
TSXV
BRAC.P
Brachium Capital
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés